Accelerate Brain Cancer Cure Commends the Selection of Brain Cancer
for Inclusion in The Cancer Genome Atlas Pilot Project

WASHINGTON, Sept. 13 - Accelerate Brain Cancer Cure today commended the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) for their announced selection of brain cancer, or glioblastoma (GBM), as one of three cancers being included in their first-ever pilot project for The Cancer Genome Atlas (TCGA).

The goal of TCGA is to map genetic changes associated with all types of cancer in the human genetic blueprint. The cancers that will be studied in the TCGA Pilot Project are GBM, lung, and ovarian. These cancers were selected because of the availability of biospecimen collections that met TCGA's rigorous scientific, technical, and ethical requirements.

The Atlas will commence its study in late 2006 or 2007 and is expected to take three years to complete. This project will utilize existing genetic resources, including carefully preserved cancer tissue donated by patients.

GBM, the most frequent type of malignant brain tumors, grow and spread aggressively and are often fatal. The average one-year survival rate for a patient diagnosed with GBM is less than 30 percent and the average five-year survival rate is only about three percent.

"Brain cancer remains one of the most extraordinarily complex, virulent, and 'orphaned' diseases. The inclusion of this deadly form of brain cancer in the TCGA Pilot Project is an encouraging development for the research community. Further, this project gives GBM patients added reason for hope and underscores the importance of their enrollment in clinical trials," stated Kate Carr, President and CEO of Accelerate Brain Cancer Cure. "Accelerate Brain Cancer Cure works to advance translational research that holds significant near-term potential for curing brain cancer and we believe this project could play an integral part in achieving a cure."

About Accelerate Brain Cancer Cure
Accelerate Brain Cancer Cure (ABC2) is a not-for-profit organization with a for-profit mindset and a singular focus: to hasten the discovery of a cure for brain cancer. ABC2 was founded in May 2001 by Dan and Steve Case and their families, along with leading scientists and entrepreneurs. ABC2 funds outstanding and novel translational science and aims to raise awareness about brain cancer to help mobilize critical scientific research through research grants and partnerships.

Additional information can be found at

For more information on The Cancer Genome Atlas:

For media inquiries or other information, please contact:
Laura Feinberg 202.419.3140 or [email protected]